Global Neurodegenerative Disorder Therapeutics Market Overview
Neurodegenerative disorders are a group of circumstances that affect the central nervous system. They involves both hereditary and sporadic conditions that are categorized by slow, irreversible, progressive dysfunction of the nervous system with the swelling degeneration of neurons. It causes symptoms such as memory loss, motor impairment, and declining cognitive ability. Currently, neurodegenerative disorders cannot be cured. Treatment is based on managing the disease indication in order to decrease the severity of symptoms and slow progression. The neurodegenerative disorder therapeutics market accounted for US$ 9.32 billion in 2019 and is estimated to be US$ 21.3 billion by 2029 and is anticipated to register a CAGR of 8.7%.
Impact of COVID-19 on the market
Several therapeutic regimens are being followed across the world in attempts to come up with a reliable treatment for Covid-19. The growing number of cases and fatalities is distressing mental health by elevating anxiety across the world. People who are already experiencing mental health problems are facing increased stress levels over the Covid-19 outbreak. This report will quantify the impact of this pandemic on the neurodegenerative disorder therapeutics market.
Global Neurodegenerative Disorder Therapeutics Market Dynamics
Increased prevalence of neurodegenerative disorder
Growth in the prevalence of neurodegenerative among the population drives the growth of neurodegenerative disorder therapeutics market. Rise in the number of geriatric population, results to the increased occurrence of neurodegenerative disorders. In 2017, as per World Population Prospects, the number of people above 60 years of age will increase from 962 million in 2017 to 2.1 billion in 2050 and it is estimated that people aged over 80 years will triple from 137 million in 2017 to 425 million in 2050. Further, according to data published by Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is expected to grow to around 14 million by 2050. Thus, growing number of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby boosting the market growth.
Increasing collaborative partnerships
Prominent players involved in the neurodegenerative disorder therapeutics are adopting multiple strategic partnerships with government and non- government firms to discover and develop therapeutics for a range of neurodegenerative diseases. Additionally, manufacturers are also increasing their collaboration with other players in the market in order to expand their capabilities for research and development activities and to develop more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in October 2019, Prevail Therapeutics Inc., a USA based Biotechnology Company collaborated with Lonza, a worldwide supplier of pharma & Biotech and specialty ingredients based in Switzerland. The collaboration aimed to develop and manufacture gene therapy programs for patients of neurodegenerative diseases.
Conversely, high rates of failure in research and development (R&D) and clinical trials have always been a major challenge in the neurodegenerative disorder therapeutics market.
Global Neurodegenerative Disorder Therapeutics Market Segmentation
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
The neurodegenerative disorder therapeutics market is segmented based on the indication type, drug type, distribution, and region.
On the basis of the indication type, the neurodegenerative disorder therapeutics market is segmented into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, and other indication types. Based on the drug type, the target market is segmented into N- methyl- D- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and other drug types. On the basis of distribution, the market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.
Regional Insights:
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
In the region, the neurodegenerative disorder therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2018, the North America market dominated the target market and is expected to maintain its dominance over the forecast period. In U.S., neurodegenerative diseases have become more prevalent due to rising aging population. According to the data published by Parkinson’s Association in 2018, about 1.2 million people in the U.S are expected to be suffering from Parkinson’s disease by 2030. Along with the continuous growth in population, this disease is predicted to double between 2018 and 2026. Moreover, rising research and development (R&D) investments and favorable healthcare reimbursement policies is also propelling the target market in this region. The market in Asia Pacific is expected to witness a considerable CAGR mainly on account of increasing geriatric population.
Report Scope:
|
Attribute |
Details |
|
The base year for estimation |
2019 |
|
Forecast period |
2019 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2019 – 2029 |
|
Market Segmentation |
By Indication Type - Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types By Drug Type - N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types By Distribution - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the neurodegenerative disorder therapeutics market report based on indication type, drug type, distribution, and region.
Neurodegenerative Disorder Therapeutics Market, By Indication Type:
- Parkinson's Disease
- Alzheimer's Disease
- Multiple Sclerosis
- Huntington Disease
- Other Indication Types
Neurodegenerative Disorder Therapeutics Market, By Drug Type:
- N- methyl- D- aspartate Receptor
- Selective Serotonin Reuptake Inhibitor
- Dopamine Inhibitors
- Other Drug Types
Neurodegenerative Disorder Therapeutics Market, By Distribution:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Neurodegenerative Disorder Therapeutics Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Neurodegenerative Disorder Therapeutics Market Key Players
The key players operating in the neurodegenerative disorder therapeutics market include Biogen, Pfizer, Sanofi, Novartis, Teva Pharmaceutical, Hoffmann- La Roche Ltd, UCB, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH. Manufacturers are investing heavily on R&D to offer a strong pipeline of drugs aimed at delivering improved patient care at low costs. Popular companies adopt strategies such as enhancement of product portfolio, regional expansion, and development of advanced diagnostic methods to improve the success rate of treatment. For instance, in February 2018, Abbevie, a USA based biopharmaceutical company collaborated with Voyager Therapeutics, a clinical stage gene therapy company based in USA. The collaboration was aimed to develop and commercialize treatments for Alzheimer’s disease and other tau-related (a protein) neurodegenerative diseases.
Global Neurodegenerative Disorder Therapeutics Market Company Profile
- Biogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Pfizer
- Sanofi
- Novartis
- Teva Pharmaceutical
- Hoffmann- La Roche, Ltd.
- UCB, ACADIA Pharmaceuticals, Inc.
- Lundeck A/S
- Boehringer Ingeiheim International GmbH
“*” marked represents similar segmentation in other categories in the respective section
Global Neurodegenerative Disorder Therapeutics Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Neurodegenerative Disorder Therapeutics Strategies
- Key Questions this Study will Answer
- Market Snippet, By Indication Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Neurodegenerative Disorder Therapeutics Market, By Indication Type, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Parkinson's Disease
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Alzheimer's Disease
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Multiple Sclerosis
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Huntington Disease
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Other Indication Types
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Neurodegenerative Disorder Therapeutics Market, By Drug Type, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- N- methyl- D- aspartate Receptor
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Selective Serotonin Reuptake Inhibitor
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Dopamine Inhibitors
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Other Drug Types
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Neurodegenerative Disorder Therapeutics Market, By Distribution, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Hospital Pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Retail Pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Online Pharmacy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Neurodegenerative Disorder Therapeutics Market, By Region, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Indication Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Drug Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Distribution, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Indication Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Drug Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Distribution, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Indication Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Drug Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Distribution, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Indication Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Drug Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Distribution, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Indication Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Drug Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Distribution, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- Biogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Pfizer
- Sanofi
- Novartis
- Teva Pharmaceutical
- Hoffmann- La Roche, Ltd.
- UCB, ACADIA Pharmaceuticals, Inc.
- Lundeck A/S
- Boehringer Ingeiheim International GmbH
- Biogen
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The neurodegenerative disorder therapeutics market is segmented based on the indication type, drug type, distribution, and region.
Advancements in precision medicine, gene therapy, and targeted drug delivery present significant opportunities in the global neurodegenerative disorder therapeutics market.
The Neurodegenerative Disorder Therapeutics Market report typically considers regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East.
The key players operating in the neurodegenerative disorder therapeutics market include Biogen, Pfizer, Sanofi, Novartis, Teva Pharmaceutical, Hoffmann- La Roche Ltd, UCB, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH.
Neurodegenerative disorder therapeutics market accounted for US$ 9.32 billion in 2019 and is estimated to be US$ 21.3 billion by 2029 and is anticipated to register a CAGR of 8.7%